MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Example Regimen Definition: PHD (Pertuzumab + Trastuzumab + Docetaxel)

Raw xml | Download

<PlanDefinition xmlns="http://hl7.org/fhir">
  <id value="RegimenPHD"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/us/codex-mopa/StructureDefinition/anticancer-regimen-plandefinition"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
  <table class="narrative-table">
    <tbody>
<tr>


<th colspan="2" scope="row" class="row-header">Metadata</th>


</tr>

<tr>


<th scope="row" class="row-header">Title</th>



<td class="content-container">PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer</td>


</tr>



<tr>


<th scope="row" class="row-header">Version</th>



<td class="content-container">0.1.1-snapshot-080926</td>


</tr>













<tr>


<th scope="row" class="row-header">Experimental</th>



<td class="content-container">true</td>


</tr>



<tr>


<th scope="row" class="row-header">Subject Type</th>



<td class="content-container">
    Malignant neoplasm of breast


</td>


</tr>



<tr>


<th scope="row" class="row-header">Jurisdiction</th>



<td class="content-container">
    United States of America


</td>


</tr>








<tr>


<th scope="row" class="row-header">Steward (Publisher)</th>



<td class="content-container">HL7 International / Clinical Interoperability Council</td>


</tr>



<tr>


<th scope="row" class="row-header">Steward Contact</th>



<td class="content-container">HL7 International / Clinical Interoperability Council</td>


</tr>







<tr>


<th scope="row" class="row-header">Description</th>



<td class="content-container"><div><p>PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial.</p>
</div></td>


</tr>






<tr>


<th scope="row" class="row-header">Type</th>



<td class="content-container">
    Order Set


</td>


</tr>




<tr>


<th colspan="2" scope="row" class="row-header">PlanDefinition Action</th>


</tr>

<tr>


<th scope="row" class="row-header">Id</th>



<td class="content-container">pertuzumab-phd</td>


</tr>




<tr>


<th scope="row" class="row-header">Title</th>



<td class="content-container">Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d</td>


</tr>













<tr>


<th scope="row" class="row-header">Timing</th>



<td class="content-container">Once per 21 days</td>


</tr>














<tr>


<th colspan="2" scope="row" class="row-header">PlanDefinition Action</th>


</tr>

<tr>


<th scope="row" class="row-header">Id</th>



<td class="content-container">trastuzumab-phd</td>


</tr>




<tr>


<th scope="row" class="row-header">Title</th>



<td class="content-container">Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d</td>


</tr>













<tr>


<th scope="row" class="row-header">Timing</th>



<td class="content-container">Once per 21 days</td>


</tr>














<tr>


<th colspan="2" scope="row" class="row-header">PlanDefinition Action</th>


</tr>

<tr>


<th scope="row" class="row-header">Id</th>



<td class="content-container">docetaxel-phd</td>


</tr>




<tr>


<th scope="row" class="row-header">Title</th>



<td class="content-container">Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle</td>


</tr>













<tr>


<th scope="row" class="row-header">Timing</th>



<td class="content-container">Once per 21 days</td>


</tr>
















<tr>
  <th colspan="2" scope="row" class="row-header">Generated using version 0.5.4 of the sample-content-ig Liquid templates</th>
</tr>

    </tbody>
  </table>
</div>
  </text>
  <url value="http://hl7.org/fhir/us/codex-mopa/PlanDefinition/RegimenPHD"/>
  <version value="0.1.1-snapshot-080926"/>
  <name value="RegimenPHD"/>
  <title
         value="PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer"/>
  <type>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
      <code value="order-set"/>
      <display value="Order Set"/>
    </coding>
  </type>
  <status value="active"/>
  <experimental value="true"/>
  <subjectCodeableConcept>
    <coding>
      <system value="http://snomed.info/sct"/>
      <code value="254837009"/>
      <display value="Malignant neoplasm of breast"/>
    </coding>
  </subjectCodeableConcept>
  <date value="2026-09-08T18:17:28-04:00"/>
  <publisher value="HL7 International / Clinical Interoperability Council"/>
  <contact>
    <name value="HL7 International / Clinical Interoperability Council"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/cic"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="ciclist@lists.HL7.org"/>
    </telecom>
  </contact>
  <description
               value="PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="US"/>
      <display value="United States of America"/>
    </coding>
  </jurisdiction>
  <action id="pertuzumab-phd">
    <title value="Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d"/>
    <timingTiming>
      <repeat>
        <period value="21"/>
        <periodUnit value="d"/>
      </repeat>
    </timingTiming>
  </action>
  <action id="trastuzumab-phd">
    <title value="Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d"/>
    <timingTiming>
      <repeat>
        <period value="21"/>
        <periodUnit value="d"/>
      </repeat>
    </timingTiming>
  </action>
  <action id="docetaxel-phd">
    <title value="Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle"/>
    <timingTiming>
      <repeat>
        <period value="21"/>
        <periodUnit value="d"/>
      </repeat>
    </timingTiming>
  </action>
</PlanDefinition>